Research institution
Centre Hospitalier Universitaire de Besancon Clinical Trials
Studies where Centre Hospitalier Universitaire de Besancon is the lead sponsor: what is enrolling now, by phase, condition and country.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 55Depression Disorder, Post Traumatic Stress Disorder PTSD
The Effects of Extreme Prematurity on Parenting
In France, perinatal mental health has become a major public health issue. Maternal mental health conditions can have serious consequences, including death by suicide.
- Trial name
- PREMA-PSY (NCT07918365)
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Metastatic Colorectal Cancer
Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers
The main objective is to evaluate the impact of a Regorafenib combined with metronomic chemotherapy (capecitabine and cyclophosphamide) and low-dose aspirin compared to standard Regorafenib treatment in patients with metastatic…
- Trial name
- CARE (NCT06425133)
- Testing
- Blood sample, Quality of life questionnaires, Biopsy
- Where
- 13 sites in France
- Volunteers
- 174 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Advanced Biliary Tract Carcinoma
MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma
In the present TACTIC clinical trial, the investigators propose to determine the clinical interest and immunological efficacy of a treatment combining MP0317 the FAP (Fibroblast Activation Protein)-dependent CD40 agonist, with…
- Trial name
- TACTIC (NCT07036380)
- Testing
- MP0317 + Gemcitabine + Cisplatine + Durvalumab, CT-Scan, Gemcitabine + Cisplatin + Durvalumab
- Where
- 11 sites in France
- Volunteers
- 75 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Renal Impairment, Digestive Cancers
DESIR. Evaluation of the Pre-therapeutic Activity of Dihydropyrimidine dEShydrogenase (DPD) in Patients With Cancer and/or Renal Failure
Fluoropyrimidine drugs (5-Fluorouracil or 5-FU and its prodrug capecitabine) are a widely used in the treatment of numerous solid tumors in adults.
- Conditions
- Renal Impairment, Digestive Cancers, Breast Cancer
- Trial name
- DESIR (NCT07124403)
- Testing
- blood sampling
- Volunteers
- 742 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Venous Congestion
VEXUS-REA : Evaluation of Ultrasound Parameters of Venous Congestion in Patients in a Medical Intensive Care Unit
Shock is a common and serious cause of admission to intensive care. Vascular filling is one of the cornerstones of shock treatment, aimed at increasing cardiac output and restoring adequate organ perfusion through rapid…
- Trial name
- VEXUS-REA (NCT07438015)
- Testing
- Venous ultrasound (inferior vena cava, portal vein, suprahepatic vein, and renal vein to calculate the VEXUS score ; femoral vein and popliteal vein)
- Where
- France
- Volunteers
- 525 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Stage IIB Melanoma, Stage IIC Melanoma
Neoadjuvant Pembrolizumab in Patients With High Risk, Stage IIB/IIC Cutaneous Melanoma: a Single Arm Proof of Concept Phase IIA Study.
This phase II trial examine whether neoadjuvant PD-1 blockade will achieve a pathological response with manageable toxicity in stage IIB/IIC melanoma.
- Trial name
- NEOSTART (NCT07883759)
- Testing
- Pembrolizumab neoadjuvant treatment, surgery, Adjuvant treatment
- Where
- 2 sites in France
- Volunteers
- 19 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Pregnant Women
Performance and Safety of Assisted Vaginal Delivery With the Odon Device™ Versus Vacuum Extraction
This is a pivotal study designed to demonstrate the non-inferiority of the Odon Device™ versus vacuum extraction
- Trial name
- E-SAFE-ODON (NCT07862842)
- Testing
- Experimental: The BD Odon DeviceTM, Active Comparator: Vacuum extraction group
- Volunteers
- 628 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)
Characteristics and Management of Patients With Severe Chronic Spontaneous and/or Inducible Urticaria Refractory to Optimized Omalizumab Treatment: A French Multicenter Observational Study.
The study is sponsored by the University Hospital of Besancon under the coordination of Dr. Julie Castagna from the Department of Dermatology and Allergology.
- Trial name
- OMADROP (NCT07833696)
- Testing
- drug effect
- Where
- France
- Volunteers
- 73 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Acute Hypoxemic Respiratory Failure, Hypoxemia
Evaluation of the FreeO2 System for Oxygen Weaning After Acute Hypoxemic Respiratory Failure
Acute hypoxemic respiratory failure (AHRF) is a common condition associated with substantial morbidity, mortality, and healthcare resource utilization.
- Trial name
- EVOLUERA (NCT07794124)
- Testing
- FreeO2 automated oxygen titration system, Standard oxygen weaning
- Volunteers
- 40 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Hepatocellular Carcinoma
Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Durvalumab
Several cancer immunotherapies that target the PD-L1/PD-1 pathway (i.e., checkpoint inhibitors) show promising clinical activity in patients with HCC.
- Trial name
- PREDICT-HCC (NCT06796114)
- Testing
- blood sample
- Where
- 10 sites in France
- Volunteers
- 120 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Completed, with results posted
All 1Solar Urticaria
Omalizumab in Severe and Refractory Solar Urticaria
Solar urticaria is a rare disease, with a usual favourable outcome with photoprotection and with anti H1 histamines. Nevertheless, some cases can be severe and refractory to this usual treatment, leading to a large impact on…
- Trial name
- XOLUS (NCT02262130)
- Testing
- Omalizumab
- Where
- 13 sites in France
- Volunteers
- 10 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon